ANALVIS CUESTA: Open Payments
NPI 1306306428 · DOUGLASVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,377 in 156 payments from 38 companies in 2025. Trend: 2023 $1,275 · 2024 $2,715 · 2025 $4,377
Food & beverage: $3,234Long term medical supply or device loan: $897Education: $245
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $1,125 |
| AstraZeneca Pharmaceuticals LP | 16 | $379 |
| PFIZER INC. | 13 | $287 |
| Merck Sharp & Dohme LLC | 8 | $201 |
| ABBVIE INC. | 7 | $181 |
| Daiichi Sankyo Inc. | 8 | $168 |
| Janssen Biotech, Inc. | 7 | $150 |
| Incyte Corporation | 5 | $147 |
| GENZYME CORPORATION | 5 | $143 |
| JAZZ PHARMACEUTICALS INC. | 4 | $138 |
Products named: KISQALI, ENHERTU, KEYTRUDA, SARCLISA, ZEPZELCA, VENCLEXTA, BRUKINSA, IBRANCE.
Industry payments across GA — which companies pay providers there.
